Get the Stockscreener App
1.29
0.78%
0.01
After Hours:
1.31
0.02
+1.55%
Standard Biotools Inc stock is traded at $1.29, with a volume of 804.49K.
It is up +0.78% in the last 24 hours and up +0.00% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
See More
Previous Close:
$1.28
Open:
$1.31
24h Volume:
804.49K
Relative Volume:
0.63
Market Cap:
$492.77M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-1.3579
EPS:
-0.95
Net Cash Flow:
$-46.12M
1W Performance:
-2.27%
1M Performance:
+0.00%
6M Performance:
+12.17%
1Y Performance:
-31.75%
1-Day Range:
$1.27
$1.3299
1-Week Range:
$1.27
$1.37
52-Week Range:
$0.92
$2.32
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
2 TOWER PLACE, SOUTH SAN FRANCISCO
Compare LAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.29 | 488.95M | 106.34M | -74.66M | -46.12M | -0.95 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Is Standard BioTools Inc. stock cheap compared to fundamentalsMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Applying sector rotation models to Standard BioTools Inc.Quarterly Profit Report & AI Based Buy/Sell Signal Reports - newser.com
What dividend safety rating applies to Standard BioTools Inc. (FLB) stockJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
How high can Standard BioTools Inc. stock goWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Standard BioTools cut to Neutral at KeyBanc on guidance - MSN
Can swing trading help recover from Standard BioTools Inc. lossesGold Moves & AI Forecast for Swing Trade Picks - newser.com
Standard BioTools' (LAB) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Standard BioTools’ (LAB) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
Can Standard BioTools Inc. hit a new high this monthPortfolio Return Summary & Expert Approved Trade Ideas - newser.com
What recovery options are there for Standard BioTools Inc.Take Profit & Verified Entry Point Signals - newser.com
How Standard BioTools Inc. stock compares to growth peersWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Will a bounce in Standard BioTools Inc. offer an exitInsider Buying & Accurate Entry/Exit Alerts - newser.com
Is Standard BioTools Inc a good long term investmentSwing Trading Watchlist & Invest Now – Opportunity Window Closing - earlytimes.in
Is Standard BioTools Inc FLB a good long term investmentEconomic Impact on Stocks & Access Our Free Weekly Investment Letter - earlytimes.in
Standard BioTools Inc Stock Analysis and ForecastStock Valuation Metrics & Free Unlock Exclusive Strategies - earlytimes.in
What drives Standard BioTools Inc stock priceSupport Level Holds & Low Cost Stock Picks - earlytimes.in
What analysts say about Standard BioTools Inc stockStock Buyback Announcements & Minimal Investment Profits - earlytimes.in
What analysts say about Standard BioTools Inc FLB stockBlue Chip Stock Analysis & Exceptional Profit Trading - earlytimes.in
Standard BioTools jumps on sale of SomaLogic to Illumina - MSN
Goldman Sachs Group Inc. Cuts Stock Position in Standard BioTools Inc. $LAB - MarketBeat
Portfolio Shifts: Will Standard BioTools Inc. face regulatory challengesVolume Spike & Fast Exit and Entry Strategy Plans - خودرو بانک
Earnings Miss: Can Standard BioTools Inc scale operations efficientlyJuly 2025 Closing Moves & Safe Entry Momentum Tips - خودرو بانک
Volatility Watch: Is RFPRFs ROIC above industry averageQuarterly Earnings Summary & Verified Short-Term Trading Plans - khodrobank.com
Pacific Capital Partners Ltd Sells 200,000 Shares of Standard BioTools Inc. $LAB - MarketBeat
Buyback Watch: How does Standard BioTools Inc correlate with NasdaqTrade Risk Assessment & Fast Entry Momentum Alerts - خودرو بانک
ETF Watch: Is Standard BioTools Inc impacted by rising ratesWeekly Trend Report & Weekly Stock Breakout Alerts - خودرو بانک
CEO Change: Is Standard BioTools Inc impacted by rising ratesStop Loss & Reliable Volume Spike Alerts - خودرو بانک
Breakout Watch: Is APPS a strong candidate for buy and holdM&A Rumor & High Accuracy Swing Entry Alerts - خودرو بانک
Standard BioTools announces workforce reduction and restructuring plan By Investing.com - Investing.com Canada
Standard BioTools announces workforce reduction and restructuring plan - Investing.com India
Standard BioTools to Cut 15% of Workforce Amid Restructuring - 富途牛牛
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Standard Biotools Inc Stock (LAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L | Director |
Sep 04 '25 |
Buy |
1.28 |
250,000 |
319,350 |
60,775,000 |
| Casdin Partners Master Fund, L | Director |
Sep 03 '25 |
Buy |
1.27 |
250,000 |
316,400 |
60,525,000 |
| Casdin Partners Master Fund, L | Director |
Aug 22 '25 |
Buy |
1.26 |
200,000 |
252,680 |
59,950,000 |
| Casdin Partners Master Fund, L | Director |
Aug 25 '25 |
Buy |
1.24 |
200,000 |
248,180 |
60,150,000 |
| Casdin Partners Master Fund, L | Director |
Aug 26 '25 |
Buy |
1.26 |
125,000 |
157,938 |
60,275,000 |
| Casdin Partners Master Fund, L | Director |
Aug 15 '25 |
Buy |
1.22 |
150,000 |
183,210 |
59,750,000 |
| Casdin Partners Master Fund, L | Director |
Aug 14 '25 |
Buy |
1.21 |
133,220 |
161,543 |
59,600,000 |
| Casdin Partners Master Fund, L | Director |
Aug 13 '25 |
Buy |
1.31 |
75,000 |
98,280 |
59,466,780 |
| Kim Hanjoon Alex | Chief Financial Officer |
May 23 '25 |
Sale |
0.94 |
1,428 |
1,344 |
930,286 |
| Mackay Sean | SVP & Chief Business Officer |
May 23 '25 |
Sale |
0.94 |
13,217 |
12,437 |
843,076 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):